Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages
Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among […]
More Stories
Insider Selling: PennyMac Financial Services, Inc. (NYSE:PFSI) Director Sells 600 Shares of Stock
PennyMac Financial Services, Inc. (NYSE:PFSI – Get Free Report) Director Doug Jones sold 600 shares of the firm’s stock in...
Head-To-Head Analysis: Bird Construction (OTCMKTS:BIRDF) vs. Técnicas Reunidas (OTCMKTS:TNISF)
Técnicas Reunidas (OTCMKTS:TNISF – Get Free Report) and Bird Construction (OTCMKTS:BIRDF – Get Free Report) are both industrials companies, but...
Short Interest in Pets at Home Group Plc (OTCMKTS:PAHGF) Grows By 244.4%
Pets at Home Group Plc (OTCMKTS:PAHGF – Get Free Report) was the recipient of a significant increase in short interest...
Ecofin Sustainable and Social Impact Term Fund (NYSE:TEAF) Short Interest Update
Ecofin Sustainable and Social Impact Term Fund (NYSE:TEAF – Get Free Report) saw a significant growth in short interest in...
Nanosonics Limited (OTCMKTS:NNCSF) Short Interest Update
Nanosonics Limited (OTCMKTS:NNCSF – Get Free Report) saw a significant increase in short interest in December. As of December 15th,...
Short Interest in Pan Pacific International Holdings Co. (OTCMKTS:DQJCY) Rises By 611.1%
Pan Pacific International Holdings Co. (OTCMKTS:DQJCY – Get Free Report) was the target of a large growth in short interest...